Lates News

Pfizer Inc. rose 2.1% in early trading. It is reported that Pfizer Inc. is set to acquire weight loss drug manufacturer Metsera for $7.3 billion. The deal values Metsera at $47.50 per share, with an additional $22.50 linked to performance milestones, representing a 42.5% premium to its latest closing price. This acquisition aligns with Pfizer's strategy to expand its product portfolio in the growing weight loss drug market.